Harvard Bioscience Inc. (HBIO) PT Raised to $7 at Benchmark, 'Q1 Beat & Raise; Outlook Improving; Raising Price Target'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- US stock futures gain ahead of July inflation data
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Harvard Bioscience Announces First Quarter 2023 Financial Results
April 25, 2023 8:01 AM EDTQ1 Revenues of $30 million up 4% over prior year periodQ1 GAAP Operating Income of $1.7 million up from a loss of $6.7 million prior yearQ1 Adjusted Operating Income of $4.4 million up from $2.4 million prior year
HOLLISTON, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the Company) today announced financial results for the first quarter ended March 31, 2023.
First quarter revenues were $30.0 million, up 4% versus $28.8 million in Q1 22. Reported revenue includes an unfavorable foreign exchange impact of... More
Harvard Bioscience Announces First Quarter 2023 Financial Results
April 25, 2023 8:01 AM EDTQ1 Revenues of $30 million up 4% over prior year periodQ1 GAAP Operating Income of $1.7 million up from a loss of $6.7 million prior yearQ1 Adjusted Operating Income of $4.4 million up from $2.4 million prior year
HOLLISTON, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the Company) today announced financial results for the first quarter ended March 31, 2023.
First quarter revenues were $30.0 million, up 4% versus $28.8 million in Q1 22. Reported revenue includes an unfavorable foreign... More
